Posts by: Charles Moore

Charles Moore

Charles Moore has a long-proven track record in both print and digital journalism, touching on a wide range of subjects, from biotech and healthcare to politics and technology. He contributes substantial feature articles research and development for the news site, particularly pertaining to technology.

March 16, 2017March 16, 2017

Asbestos Disease Awareness Group Protests House Passage of FACT Act

News

Linda Reinstein, president and CEO of the Asbestos Disease Awareness Organization (ADAO), has released a sharply worded statement protesting the U.S. House of Representatives’ passage of the Furthering Asbestos Claim ... Read more

February 27, 2017

Victor Dahdaleh Foundation Officially Gives BLF £5M for Mesothelioma Research

News

A Feb. 23 signing ceremony at Great Britain’s House of Lords made the Victor Dahdaleh Foundation‘s recent £5 million ($6.2 million) donation to the British Lung Foundation (BLF) official. The ... Read more

July 19, 2016July 19, 2016

NCCN Panel Favors New Mesothelioma Drug Combo as First-Line Therapy

News

The National Comprehensive Cancer Network (NCCN), an alliance of 27 major U.S. cancer centers, has expanded its recommendation for first-line pleural mesothelioma treatment to include the monoclonal antibody drug Avastin (bevacizumab) as a combination therapy ... Read more

July 5, 2016July 5, 2016

US Asbestos Ban Draws Closer with New Substances Regulation, Management Law

News

On June 22, President Barack Obama signed the Frank R. Lautenberg Chemical Safety for the 21st Century Act into law. The legislation, which received bipartisan support by the U.S. House ... Read more

December 29, 2015December 29, 2015

Inherited Mesothelioma-causing Mutation May Link 80,000 People to 1 Immigrant Couple

News

A new study suggests that as many as 80,000 Americans, all thought to be descendants of an immigrant couple, may be at higher risk for mesothelioma because of a genetic mutation ... Read more

December 15, 2015December 15, 2015

Study Of Amatuximab For First-Line, Unresectable, Malignant Pleural Mesothelioma Patients Launched

News

Exton, Pennsylvania based Morphotek, Inc., the U.S. biopharmaceutical subsidiary of Tokyo-based global health care pharmaceutical company Eisai Co.,Ltd. — specializing in development of protein and antibody products through use of novel ... Read more

December 8, 2015December 8, 2015

Positive WT1 Cancer Vaccine Clinical Trial Results For Mesothelioma, Other Cancers Reported At International WT1 Conference

News

Zug, Switzerland, based SELLAS Life Sciences Group, (SELLAS), a 2012 startup clinical-stage biopharmaceutical company focused on development of novel cancer therapies, reports that positive data from the company’s clinical studies ... Read more